Business Context and Reporting Period
This Form 8-K filing by NantKwest, Inc. (not Immunitybio, Inc.) reports on the 2017 Annual Meeting of Stockholders held on June 9, 2017. The company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 82,155,862 shares outstanding as of the April 17, 2017 record date, 73,839,241 shares (approximately 89.88%) were represented at the meeting. The following matters were voted upon:
- Election of Directors: All seven nominees were elected to serve until the 2018 annual meeting. Significant broker non-votes (8,548,152) were recorded for each director.
- Ratification of Auditors: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the company name discrepancy between the request metadata (Immunitybio, Inc.) and the filing content (NantKwest, Inc.).
- Confirm the high percentage of broker non-votes (approx. 11.6% of outstanding shares) regarding director elections.
- Review the full proxy statement for detailed biographical information on the elected directors.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.